Keyphrases
Hemophilia
81%
Bleeding
51%
Venous Thromboembolism
44%
Severe Haemophilia A
41%
Recombinant Activated Factor VII (rFVIIa)
38%
Neonate
30%
Pediatric
27%
Emicizumab
25%
Thrombin Generation
24%
Thrombophilia
24%
Hemophilia Patients
20%
Hemostasis
20%
Hemophilia B
20%
Thrombosis
20%
Risk Factors
19%
Pediatric Patients
18%
Recurrent Venous Thromboembolism
17%
Platelets
14%
Inhibitor Development
14%
Factor VIII (FVIII)
13%
Major Bleeding
12%
Inherited Thrombophilia
12%
Bleeding Episodes
12%
Anticoagulation
11%
Thromboembolism
11%
Confidence Interval
11%
Rivaroxaban
10%
Factor VIII Inhibitor
10%
Annualized Bleeding Rate
9%
Thromboelastography
9%
Preterm Infants
9%
Thrombocytopenia
9%
Platelet Function
9%
Immune Tolerance Induction
8%
Antiphospholipid Syndrome
8%
Older Adults
8%
Thrombosis Risk
8%
Multicenter Cohort Study
8%
Glanzmann Thrombasthenia
8%
Bleeding Disorders
7%
Anticoagulant Therapy
7%
Haemophilia with Inhibitors
7%
Antiphospholipid Antibodies
7%
Coagulation
7%
Von Willebrand Disease
7%
Venous Thrombosis
7%
Previously Treated
7%
Cerebral Venous Thrombosis
7%
Bleeding Tendency
7%
Long-term Efficacy
7%
Medicine and Dentistry
Haemophilia A
84%
Bleeding
48%
Venous Thromboembolism
38%
Pediatrics
34%
Thrombophilia
28%
Neonate
26%
Thrombosis
25%
Blood Stasis
25%
Patient with Hemophilia
24%
Thrombin
19%
Haemophilia B
19%
Blood Clotting Factor 8
17%
Cohort Analysis
17%
Emicizumab
17%
Hemostat
17%
Ciclonicate
17%
Platelet
14%
Diseases
14%
Pediatrics Patient
13%
Bleeding Disorder
13%
Anticoagulant Therapy
13%
Factor VII
13%
Thromboembolism
12%
Recurrent Disease
12%
Thrombocyte Function
11%
Cerebral Hemorrhage
11%
Systematic Review
10%
Thromboelastography
9%
Major Bleeding
9%
Central Venous Catheter
8%
Apoplexy
8%
Immunological Tolerance
8%
Meta-Analysis
8%
Antiphospholipid Syndrome
7%
Bleeding Diathesis
7%
Phlebothrombosis
7%
Pulmonary Embolism
7%
Recombinant Blood Clotting Factor 7a
7%
Protein C
7%
Substitution Therapy
7%
Prothrombin
7%
Anticoagulation
7%
Prematurity
7%
Glanzmann's Thrombasthenia
6%
Gene Therapy
6%
Malignant Neoplasm
6%
Thrombocytopenia
6%
Antiphospholipid Antibody
6%
Protein S Deficiency
5%
Quality of Life
5%
Pharmacology, Toxicology and Pharmaceutical Science
Haemophilia A
100%
Bleeding
53%
Venous Thromboembolism
34%
Ciclonicate
27%
Emicizumab
24%
Blood Clotting Factor 8
23%
Thrombin
18%
Blood Clotting Factor 7
16%
Haemophilia B
15%
Thrombophilia
13%
Blood Stasis
13%
Recombinant Blood Clotting Factor 7a
13%
Anticoagulant Agent
12%
Diseases
12%
Thrombosis
11%
Hemostatic Agent
11%
Recurrent Disease
11%
Cohort Study
10%
Brain Hemorrhage
9%
Bleeding Disorder
9%
Rivaroxaban
9%
Thromboembolism
9%
Clinical Trial
8%
Recombinant Blood Clotting Factor 8
8%
Adverse Event
8%
Blood Clotting Factor 8 Inhibitor
6%
Von Willebrand Factor
6%
Blood Clotting Factor 9
6%
Von Willebrand Disease
6%
Prothrombin
6%
Replacement Therapy
5%
Antithrombin
5%
Blood Clotting Factor
5%
Direct Oral Anticoagulant
5%
Hemarthrosis
5%
Malignant Neoplasm
5%